Orynbayeva Zulfiya

From Bioblast
Revision as of 11:26, 19 November 2021 by Tindle Lisa (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision β†’ (diff)


MiPsociety
News and Events        
BEC 2020.1 Mitochondrial physiology
       
MitoEAGLE
        Working Groups         Short-Term Scientific Missions         Management Committee         Members        
MitoGlobal
   


EU-logo.jpg

COST Action CA15203 (2016-2021): MitoEAGLE
Evolution-Age-Gender-Lifestyle-Environment: mitochondrial fitness mapping


Orynbayeva Zulfiya


MitoPedia topics: EAGLE 

COST: Member COST WG1: WG1


Name Orynbayeva Zulfiya, PhD ORCID ID
Institution
Zulfiya Orynbayeva
Zulfiya joined Oroboros Instruments from October 2020 to February 2021.
Address ,
City Warminster
State/Province Pennsylvania (PA)
Country USA
Email
Weblink
O2k-Network Lab AT Innsbruck Oroboros, US PA Philadelphia Orynbayeva Z



Bioenergetics Communications

Keywords: mitochondria, oncology, neurodegeneration

Participated

Labels:

Topics: Mitochondria, permeability transition, respiration, ROS system, cancer cell physiology 


Publications

 PublishedReference
Gainutdinov 2022 MitoFit2022Gainutdinov T, Debska-Vielhaber G, Gizatullina Z, Vielhaber S, Orynbayeva Z, Gellerich FN (2022) Impaired Ca2+ signalling as an indicator of disturbed mitochondrial function in fibroblasts from patients with sporadic and familial ALS. https://doi.org/10.26124/mitofit:2022-0015.v2 β€” 2022-12-09 published in Bioenerg Commun 2022.18.
Gainutdinov 2022 BEC2022Gainutdinov T, Debska-Vielhaber G, Gizatullina Z, Vielhaber S, Orynbayeva Z, Gellerich FN (2022) Impaired Ca2+ signaling indicates disturbed mitochondrial function in fibroblasts from patients with sporadic and familial ALS. Bioenerg Commun 2022.18. https://doi.org/10.26124/bec:2022-0018
BEC 2020.1 doi10.26124bec2020-0001.v12020Gnaiger E et al ― MitoEAGLE Task Group (2020) Mitochondrial physiology. Bioenerg Commun 2020.1. https://doi.org/10.26124/bec:2020-0001.v1
Charles 2020 Nanomedicine (Lond)2020Charles C, Cohen-Erez I, Kazaoka B, Melnikov O, Stein DE, Sensenig R, Rapaport H, Orynbayeva Z (2020) Mitochondrial responses to organelle-specific drug delivering nanoparticles composed of polypeptide and peptide complexes. Nanomedicine (Lond) 15:2917-32.
Altinok 2019 J Cell Physiol2019Altinok O, Poggio JL, Stein DE, Bowne WB, Shieh AC, Snyder NW, Orynbayeva Z (2019) Malate-aspartate shuttle promotes l-lactate oxidation in mitochondria. J Cell Physiol 235:2569-81.
Nacarelli 2018 Geroscience2018Nacarelli T, Azar A, Altinok O, Orynbayeva Z, Sell C (2018) Rapamycin increases oxidative metabolism and enhances metabolic flexibility in human cardiac fibroblasts. Geroscience 40:243-56.
Irgebay 2017 Breast2017Irgebay Z, Yeszhan B, Sen B, Tuleukhanov S, Brooks AD, Sensenig R, Orynbayeva Z (2017) Danazol alters mitochondria metabolism of fibrocystic breast Mcf10A cells. Breast 35:55-62.
Zhunussova 2016 PLOS ONE2016Zhunussova A, Vitol EA, Polyak B, Tuleukhanov S, Brooks AD, Sensenig R, Friedman G, Orynbayeva Z (2016) Mitochondria-mediated anticancer effects of non-thermal atmospheric plasma. PLOS ONE 11:e0156818.
Orynbayeva 2015 Nanomedicine (Lond)2015Orynbayeva Z, Sensenig R, Polyak B (2015) Metabolic and structural integrity of magnetic nanoparticle-loaded primary endothelial cells for targeted cell therapy. Nanomedicine (Lond) 10:1555-68.
Gainutdinov 2015 Arch Biochem Biophys2015Gainutdinov T, Molkentin JD, Siemen D, Ziemer M, Debska-Vielhaber G, Vielhaber S, Gizatullina Z, Orynbayeva Z, Gellerich FN (2015) Knockout of cyclophilin D in Ppif(-/-) mice increases stability of brain mitochondria against Ca(2+) stress. Arch Biochem Biophys 579:40-6.
Zhunussova 2015 Am J Cancer Res2015Zhunussova A, Sen B, Friedman L, Tuleukhanov S, Brooks AD, Sensenig R, Orynbayeva Z (2015) Tumor microenvironment promotes dicarboxylic acid carrier-mediated transport of succinate to fuel prostate cancer mitochondria. Am J Cancer Res 5:1665-79.

Abstracts

 PublishedReference
Panov 2011 Abstract IOC652011Panov A, Orynbayeva Z (2011) The bioenergetic signature of prostate cancer. MiPNet16.03.
Cookies help us deliver our services. By using our services, you agree to our use of cookies.